Research Article
No access
Published Online: 29 January 2009

Open-Label Quetiapine in the Treatment of Children and Adolescents with Autistic Disorder

Publication: Journal of Child and Adolescent Psychopharmacology
Volume 9, Issue Number 2



The purpose of this trial was to investigate the short-term safety and efficacy of quetiapine fumarate in the treatment of children and adolescents with autistic disorder (AD).


This was a 16-week, open-label trial that included 6 male subjects with a mean age of 10.9 ± 3.3 years. All subjects met the DSM-IV criteria for AD and functioned in the mentally retarded range (mild, n = 2; moderate, n = 3; severe, n = 1). Behavioral ratings were obtained at baseline and every four weeks thereafter.


Overall, there was no statistically significant improvement between baseline and endpoint for the group as a whole. Only two subjects completed 16 weeks of treatment and were considered "responders" by the global improvement item of the Clinical Global Impression Scale (CGIS). Dosages ranged from 100 to 350 mg/day (1.6–5.2 mg/kg/day). Subjects dropped out prematurely because of lack of response and sedation, limiting further dose increases (n = 3), and because of a possible seizure during the fourth week of treatment (n = 1). Other significant side effects included behavioral activation, increased appetite and weight gain (range, 0.9 to 8.2 kg).


Quetiapine was poorly tolerated and associated with serious side effects in this clinical population.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors


Published In

cover image Journal of Child and Adolescent Psychopharmacology
Journal of Child and Adolescent Psychopharmacology
Volume 9Issue Number 21999
Pages: 99 - 107
PubMed: 10461820


Published online: 29 January 2009
Published in print: 1999


Request permissions for this article.




Metrics & Citations



Export citation

Select the format you want to export the citations of this publication.

View Options

Get Access

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options


View PDF/ePub







Copy the content Link

Share on social media

Back to Top